Financial
FY2025 revenue $11.24bn (+5.7%); operating margin -2.7%; net loss $957.0m.
Continuing operations; operating loss after impairment and restructuring charges.
Baxter
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: BAX
FY2025 revenue $11.24bn (+5.7%); operating margin -2.7%; net loss $957.0m.
Continuing operations; operating loss after impairment and restructuring charges.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$11.2bn | +5.7% | -US$308m | -US$957m | Baxter International |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Oct 2025: A securities class action filed in Illinois alleges Baxter misled investors about the safety of its Novum IQ large-volume infusion pump; Baxter said it intends to vigorously defend itself. Its shares fell over 20% in Jul 2025 after it paused pump installations.
Cyber & information governance
Nov 2025: HealthExec reported that the FDA had issued a full recall of Baxter Life2000 ventilators because of a serious cybersecurity flaw. NHS DSPT status not yet checked.
Regulatory & clinical safety
Jul 2025: The FDA issued an early alert on Baxter's Novum IQ large-volume infusion pumps, which can under-infuse after large rate increases; Baxter had reported 79 serious injuries and two deaths linked to the issue and issued customer instructions.
Contract performance
Jul 2025: Baxter paused planned new installations of its Novum IQ large-volume infusion pump while it addressed a flow-rate problem; existing pumps remained in use under updated instructions.
Competitors
No competitors linked yet.